<DOC>
	<DOCNO>NCT00578227</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . Vaccination pre-teens adolescent , ideally sexual debut thus exposure oncogenic HPV , rational strategy prevention cervical cancer , HPV vaccination could complement exist pre-adolescent/adolescent vaccination program . Therefore , Phase IIIb study design evaluate safety immunogenicity co-administering commercially available vaccine GSK Biologicals ' HPV-16/18 L1 AS04 ( Cervarix Â® ) vaccine compare administration either vaccine alone . This Protocol Posting update order comply FDA AA , Sept 2007 .</brief_summary>
	<brief_title>Evaluation Safety Immunogenicity Co-administering Human Papillomavirus Vaccine With Another Vaccine Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or legally acceptable representative ( LARs ) comply requirement protocol enrol study . A female , include , 9 15 year age ( attained 16th birthday ) time first vaccination . Written inform consent obtain subject prior enrolment . For subject legal age consent , write informed consent must obtain subject 's LAR , write informed assent must obtain subject . Healthy subject establish medical history clinical examination enter study . Subjects must pregnant . Subjects must nonchildbearing potential , subject childbearing potential , must abstinent use adequate contraception 30 day prior vaccination must agree continue precaution two month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period ( Month 12 ) . Concurrently participate another clinical study , time study period ( Month 12 telephone contact ) , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day dose vaccine ( ) . Administration routine vaccine may allow 8 day first dose A subject planning become pregnant , likely become pregnant planning discontinue contraceptive precaution study period two month last vaccine dose . Pregnant breastfeed woman . Previous vaccination HPV plan administration HPV vaccine foreseen study protocol study period . Previous administration component investigational vaccine . Previous vaccination hepatitis A B plan administration hepatitis A B vaccine foreseen study protocol study period . History hepatitis A B infection . Known exposure hepatitis A B within previous 6 week . Known acute chronic , clinically significant neurologic , hepatic renal functional abnormality , determine previous physical examination laboratory test . Cancer autoimmune disease treatment . History allergic disease reaction likely exacerbate component vaccine Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period .</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Human papillomavirus infection ,</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>HPV vaccine ,</keyword>
</DOC>